Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Rating) – Research analysts at Jefferies Financial Group reduced their Q2 2022 earnings per share estimates for shares of Stoke Therapeutics in a report released on Tuesday, May 10th. Jefferies Financial Group analyst S. Jeong now anticipates that the company will post earnings of ($0.71) per share for the quarter, down from their previous forecast of ($0.70). Jefferies Financial Group currently has a “Buy” rating and a $50.00 target price on the stock. Jefferies Financial Group also issued estimates for Stoke Therapeutics’ Q3 2022 earnings at ($0.73) EPS, Q4 2022 earnings at ($0.75) EPS, FY2022 earnings at ($2.84) EPS, FY2023 earnings at ($3.12) EPS, FY2024 earnings at ($2.87) EPS, FY2025 earnings at ($3.03) EPS and FY2026 earnings at ($3.37) EPS.
Stoke Therapeutics (NASDAQ:STOK – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($1.02).
STOK stock opened at $13.72 on Friday. The company has a fifty day moving average price of $19.90 and a two-hundred day moving average price of $21.07. Stoke Therapeutics has a one year low of $12.59 and a one year high of $41.60.
Several institutional investors have recently made changes to their positions in STOK. Invesco Ltd. bought a new stake in shares of Stoke Therapeutics in the second quarter valued at about $269,000. Deutsche Bank AG raised its stake in Stoke Therapeutics by 116.4% in the third quarter. Deutsche Bank AG now owns 27,195 shares of the company’s stock valued at $693,000 after purchasing an additional 14,628 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in Stoke Therapeutics by 17.4% in the third quarter. Los Angeles Capital Management LLC now owns 20,087 shares of the company’s stock valued at $511,000 after purchasing an additional 2,970 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Stoke Therapeutics in the third quarter valued at about $130,000. Finally, Goldman Sachs Group Inc. raised its stake in Stoke Therapeutics by 26.7% in the third quarter. Goldman Sachs Group Inc. now owns 172,749 shares of the company’s stock valued at $4,395,000 after purchasing an additional 36,361 shares in the last quarter. 99.87% of the stock is owned by institutional investors.
Stoke Therapeutics Company Profile (Get Rating)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.
- Get a free copy of the StockNews.com research report on Stoke Therapeutics (STOK)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.